글로벌 저프로트롬빈혈증 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력 글로벌 저프로트롬빈혈증 치료 시장

저프로트롬빈혈증 치료 시장 규모는 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 4.50%로 성장할 것으로 예상됩니다. 저프로트롬빈혈증 치료 시장에 대한 Data Bridge Market Research 보고서는 예측 기간 동안 널리 퍼질 것으로 예상되는 다양한 요소에 대한 분석과 통찰력을 제공하고 시장 성장에 미치는 영향을 제공합니다.

저프로트롬빈혈증은 기본적으로 희귀한 출혈 장애로, 후천적이거나 유전적일 수 있습니다. 이 장애에서는 혈액 응고 물질인 프로트롬빈(인자 II)이 간에서 결핍됩니다. 이 결핍은 혈액 응고 메커니즘의 기능 장애를 초래하여 자발적 출혈 의 생리적 위험이 증가합니다 .

전 세계적으로 출혈성 질환의 유병률 증가와 공중 보건 프로그램에 대한 지출 증가와 같은 성장 결정 요인은 2022년에서 2029년의 예측 기간 동안 시장 성장을 가속화할 것으로 예상됩니다. 또한, 의료 지출의 발전은 시장 성장을 위한 길을 더욱 개척할 것입니다. 이에 더하여, 증가하는 글로벌 의료 지출은 또한 위에서 언급한 예측 기간 내에 시장의 전반적인 성장을 촉진할 것으로 예상됩니다. 그러나 높은 연구 개발 비용과 높은 의료비와 같은 요인은 시장 성장률을 제한할 것으로 예상됩니다. 반면에 숙련된 전문가의 부족은 또한 시장의 전반적인 성장을 방해합니다.

Furthermore, the increase in research and development activities to launch an better treatment for hypoprothrombinemia by leading players are likely to create various new opportunities that will impact this hypoprothrombinemia treatment market growth in the forecast period of 2022 to 2029. On the flip side, the inadequate reimbursement along with the patent expiry of branded drugs are estimated to challenge the market’s growth.

This hypoprothrombinemia treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the hypoprothrombinemia treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Hypoprothrombinemia Treatment Market Scope and Market Size

Hypoprothrombinemia treatment market is segmented on the basis of types, treatment, products, drugs, route of administration, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of types, the hypoprothrombinemia treatment market is segmented into true hypoprothrombinemia (type I deficiency) and dysprothrombinemia (type II deficiency).
• On the basis of treatment, the hypoprothrombinemia treatment market is segmented as medication, preventive care and supplements.
• On the basis of products, the hypoprothrombinemia treatment market is segmented as Prothrombin Complex Concentrates (PCC) and Fresh Frozen Plasma (FFP).
• On the basis of drugs, the hypoprothrombinemia treatment market is segmented as phytomenadione, menadoxime and others.
• On the basis of route of administration, the hypoprothrombinemia treatment market is segmented into oral and parenteral.
• On the basis of distribution channel, the hypoprothrombinemia treatment market is segmented as hospital pharmacy, retail pharmacy and online pharmacy.
• On the basis of end-users, the hypoprothrombinemia treatment market is segmented into hospitals, homecare, specialty clinics and others.

Hypoprothrombinemia Treatment Market Country Level Analysis

Hypoprothrombinemia treatment market is analyzed and market size information is provided by types, treatment, products, drugs, route of administration, distribution channel and end-users as referenced above.

The countries covered in the hypoprothrombinemia treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the hypoprothrombinemia treatment market due to the availability of various advanced technologies and launch of new treatment options within this region. Asia-Pacific region, on the other hand is expected to expand at a significant growth rate because of the healthcare expenditure and rising spending on public health programs over the course of this forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Hypoprothrombinemia treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Hypoprothrombinemia Treatment Market Share Analysis

Hypoprothrombinemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hypoprothrombinemia treatment market.

저프로트롬빈혈증 치료 시장 보고서에서 활동하는 주요 기업으로는 F. Hoffmann-La Roche, Abbott, Epitomepharm, Takeda Pharmaceutical Company Limited, CSL Limited, Octapharma AG, Bayer AG, Pfizer Inc, Novo Nordisk A/S, Grifols, SA, Biogen, BioMarin, BioSyent Inc., Glenmark Pharmaceuticals Limited, AMARNA THERAPEUTICS, Alnylam Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd, Mylan NV, Integra LifeSciences, Enzo Biochem Inc, Emcure, Viramal, Emergent, Amgen Inc., Baxter, Medtronic, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC 등이 있습니다.

SKU-50525